China Tightens Regulations on Listed Company Spin-offs, Multiple Deals Shelved
nashnova research
China's securities regulator is tightening review of listed companies spinning off subsidiaries for separate listings — Goertek, Dongcheng Pharma and others have already shelved plans, while Baidu's Kunlun chip unit and other queued deals face rising uncertainty, effectively narrowing the spinoff pipeline for A-shares and Hong Kong.
What exactly is the regulator tightening?
The CSRC has two core concerns: it discourages companies from carving out their most profitable units for standalone listings, viewing such moves as unfair to existing parent-company shareholders; and it wants spun-off subsidiaries to operate in clearly distinct business areas from their parents, reducing overlap and related-party transactions.
This means → the playbook of "package the best assets into a separate equity story and raise another round" is being shut down at the regulatory gate.
Sources say the CSRC may issue more formal guidance as early as next year, though discussions are ongoing and details could change.
Which companies have already pulled back?
Goertek (歌尔股份) shelved its plan to list its micro-electronics unit in Hong Kong this month.
Yantai Dongcheng Pharma (东诚药业) dropped its Hong Kong subsidiary listing; Zhejiang Shuanghuan Driveline (双环传动) paused its robotics-unit A-share IPO in September.
In plain terms = three companies across different sectors and listing venues all hit the brakes in the same window — this signals the regulatory message has reached corporate boardrooms.
Who is still in the queue?
Zhejiang Medicine's (浙江医药) biotech subsidiary Novicord Biopharma and Shandong Gold's (山东黄金) overseas unit Shanjin International Gold are both awaiting regulatory approval.
Baidu's (百度) chip unit Kunlun (昆仑芯) is preparing a dual listing in Shanghai and Hong Kong.
This means → none of these deals have been formally blocked, but approval pace and pass rates are the key verification points the market is watching — any outright rejection would be read as hard proof of a tighter regime.
What do the deals that already went through tell us?
In July, state-owned China Resources Power (华润电力) listed its subsidiary CR New Energy Holdings in Shenzhen — one of the year's largest A-share IPOs. Hisense Group (海信集团) then spun off its optical-module unit Linsense Technology (聆感科技) onto the Hong Kong exchange.
In plain terms = the window is not fully shut, but the successful cases cluster in policy-favoured sectors — renewables, optical communications — and most cleared before the regulatory tone shifted.
This reflects a growing pattern: whether a spinoff gets approved increasingly depends on whether the business aligns with industrial policy.
How were the rules set, and why tighten now?
Current spinoff rules were established in 2022, requiring the parent to be listed with at least three years of profitability, and capping the subsidiary's share of the parent's net profit and assets. Supplementary guidance issued in subsequent years aimed to curb quick monetisation of market hype.
The immediate backdrop: volatile sentiment in AI-related sectors and broader market swings — regulators worry companies will rush spinoffs to capitalise on thematic rallies.
South Korea's regulator recently took a similarly harder line: SK Hynix's subsidiary Solidigm this week abandoned an approximately $10 billion U.S. listing due to regulatory resistance. This means → tighter spinoff oversight is not unique to China — it is part of a global regulatory cycle.
市场有风险，内容仅供研究参考，不构成投资建议。